Scinai regained compliance with Nasdaq’s $1.00 minimum bid-price requirement after its ADSs maintained a closing bid of at least $1.00 per share across the required review period. Nasdaq closed the matter, resolving the stated listing issue while management keeps its focus on commercial execution and NanoAb development.

Key Highlights

  • Scinai Biopharma Services Ltd. provides development and Manufacturing services through facilities in Jerusalem and Yavne.
  • The company identifies financing, regulatory approvals and continued Nasdaq compliance among risks affecting forward-looking statements.
  • Scinai’s American Depositary Shares regained compliance with Nasdaq’s $1.00 minimum bid-price requirement.
  • Nasdaq staff notified Scinai on March 12, 2026, and Nasdaq has closed the compliance matter.

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a Pharmaceuticals: Other company. Its American Depositary Shares have regained compliance with Nasdaq’s $1.00 minimum bid-price requirement, and Nasdaq has closed the matter.

Nasdaq Bid Threshold Met

Nasdaq staff notified Scinai on March 12, 2026, that its ADSs had fallen below the required $1.00 minimum bid price over the preceding review period. Nasdaq therefore determined that Scinai had restored compliance with Listing Rule 5550(a)(2).

Commercial Execution Remains Focus

Amir Reichman, Chief Executive Officer, said the Nasdaq confirmation closes an important compliance matter and thanked Nasdaq staff for their review and engagement. Statements covering continued commercial execution, CDMO growth, NanoAb development and ongoing listing compliance are based on current expectations and assumptions.